Drug search by name

Ticlopidine and Myelosuppression

Result of checking the interaction of drug Ticlopidine and disease Myelosuppression for safety when used together.

Check result:

Ticlopidine <> Myelosuppression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of ticlopidine is contraindicated in patients with hematopoietic disorders such as neutropenia and/or thrombocytopenia or a past history of thrombotic thrombocytopenic purpura (TTP) or aplastic anemia. Ticlopidine can cause life-threatening hematological adverse reactions, including neutropenia/agranulocytosis, TTP and aplastic anemia. Clinical monitoring of hematopoietic function is required for all patients receiving ticlopidine, since severe hematopoietic disorders may develop suddenly, usually within the first 3 weeks to 3 months of therapy. CBCs (including differential and platelet count) should be performed prior to initiation of ticlopidine and every 2 weeks through the first 3 months or as often as necessary.

References:

Garnier G, Taillan B, Pesce A, Chichmanian RM, Dujardin P "Ticlopidine and severe aplastic anaemia." Br J Haematol 81 (1992): 459-60
Martinnunez G, Fdezsoria RR, Sanchezgil F, Benitezcano E "Aplastic anaemia and ticlopidine." Br J Haematol 85 (1993): 633
Troussard X, Mayo P, Mosquet B, Reman O, Leporrier M "Ticlopidine and severe aplastic anaemia ." Br J Haematol 82 (1992): 779-80
"Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA.
Dunn P "Aplastic anemia with ticlopidine therapy in two Chinese patients." Ann Pharmacother 30 (1996): 547
Mallet L, Mallet J "Ticlopidine and fatal anemia in an elderly woman." Ann Pharmacother 28 (1994): 1169-71
Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M "Agranulocytosis caused by ticlopidine and its mechanism." Am J Hematol 37 (1991): 239-42
Arribalzaga K, Garciasuarez J, Lopezrubio M, Krsnik I, Calero MA, Delcampo JF "Sustained granulocyte recovery after g-CSF in a patient with ticlopidine-induced severe aplastic anemia." Am J Hematol 50 (1995): 313
Khelif A, Assouline D, Ffrench M, Chaumentin G, Viala JJ "Ticlopidine and aplastic anaemia." Br J Haematol 83 (1993): 678-9
Farver DK, Hansen LA "Delayed neutropenia with ticlopidine." Ann Pharmacother 28 (1994): 1344-6
Lesesve JF, Callat MP, Lenormand B, Monconduit M, Noblet C, Moore N, Caron F, Humbert G, Stamatoullas A, Tilly H "Hematological toxicity of ticlopidine." Am J Hematol 47 (1994): 149-50
Muszkat M, Shapira MY, Sviri S, Linton DM, Caraco Y "Ticlopidine-induced thrombotic thrombocytopenic purpura." Pharmacotherapy 18 (1998): 1352-5
Mataix R, Ojeda E, Perez MC, Jimenez S "Ticlopidine and severe aplastic anaemia." Br J Haematol 80 (1992): 125-6